The Biotech Growth Trust invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Find out more about us Investor Update Webinar - February 2025 View more videos Share price View share price detail ...
Return on Assets (ttm)0 % Return on Equity (ttm)0 % Qtrly Rev. Growth0 % Gross Profit (p.s.)0 Sales Per Share0 EBITDA (p.s.)0 Qtrly Earnings Growth0 % Operating Cash Flow0 (M) Levered Free Cash Flow0 (M) Stock Valuations...
Biotechnology / Pharmaceuticals Share Price Appreciation of Biotech Due Over Next Six Months Research Report (04/08/2025) Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. Biotechnology / PharmaceuticalsMore...
Dividend Growth 5 Yr (CAGR) -9.70% - -39.88% 136.53% 1 Month Price Performance -12.44% 13.02% -15.63% 5.30% 6 Month Price Performance 9.68% -14.26% 17.45% -11.70% 1Y Price Performance -11.37% 0.51% -21.70% -7.00% 5Y Price Performance ...
Price/Book (TTM) 7.56 EV/Sales (TTM) - EV/EBITDA (TTM) NM More On Valuation » GrowthProfitability Rating:view ratings Gross Profit Margin - EBIT Margin - Net Income Margin - Return on Equity -145.20% Return on Assets -113.93% More On Profitability » ...
Day’s Range― - ― 52-Week Range$6.25 - $6.58 Previous CloseN/A VolumeN/A Average Volume (3M)0.00 Market Cap $460.27M Enterprise ValueN/A Total Cash (Recent Filing)$62.43M Total Debt (Recent Filing)$9.45M Price to Earnings (P/E)― ...
commanding approximately 39% of the total market share in 2024. This significant market position is primarily driven by the increasing global focus on renewable energy resources and the pressing need to reduce carbon emissions across industries. The segment's growth is further bolstered by supportive...
The company also guided to 17% to 26% adjusted profit growth. Halozyme stock has a strong Composite Rating of 97, and a Relative Strength Rating of 92. Shares broke out of a consolidation with an entry at 65.53 on March 24. But the biotech stock later fell as much as 15% below i...
Share Price Appreciation of Biotech Due Over Next Six Months Dr. David Nierengarten (04/08/2025) Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. Tags: Biotechnology / Pharmaceuticals New Therapy for ...
pharmaceuticals, and the consumer goods and technology sectors. And despite a brief downturn at the start of 2020, the average growth in UK biotechs’ share price was 32 percent, surpassing European biotechs (22 percent) and US biotechs (2 percent), and only trailing China’s ...